Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age-Reference-Cited by-同舟云学术

Ten-year immune persistence and safety of the HPV-16/18 AS04-adjuvanted vaccine in females vaccinated at 15-55 years of age

Published:2017-10-05 Issue:11 Volume:6 Page:2723-2731
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Schwarz Tino F.¹^ORCID,Galaj Andrzej²,Spaczynski Marek³,Wysocki Jacek⁴,Kaufmann Andreas M.⁵,Poncelet Sylviane⁶,Suryakiran Pemmaraju V.⁷,Folschweiller Nicolas⁸,Thomas Florence⁸,Lin Lan⁸,Struyf Frank⁸

Affiliation:

1. Central Laboratory and Vaccination Centre; Klinikum Würzburg Mitte; Standort Juliusspital; Würzburg Germany

2. NZOZ Vitamed; Bydgoszcz Poland

3. Faculty of Medicine and Health Sciences; University of Zielona Gora; Zielona Gora Poland

4. Department of Preventive Medicine; Poznan University of Medical Sciences; Poznan Poland

5. Department of Gynecology; Charité-Universitätsmedizin Berlin; Berlin Germany

6. GSK; Rixensart Belgium

7. GSK; Bangalore India

8. GSK; Wavre Belgium

Funder

GlaxoSmithKline Biologicals SA

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Reference23 articles.

1. Human Papillomavirus is a necessary cause of invasive cervical cancer worldwide;Walboomers;J Pathol.,1999

2. ICO Information Centre on HPV and Cancer Human Papillomavirus and Related Diseases Report - World [Published 2015] http://hpvcentre.net/statistics/reports/XWX.pdf

3. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study;Sanjose;Lancet Oncol.,2010

4. European Medicines Agency EPAR summary for the public [Published 2014]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf

5. United States Food and Drug Administration October 16, 2009 Approval Letter - Cervarix [Published2009. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm.(accessed

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity;Viruses;2024-08-29

2. Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control;Viruses;2024-08-25

3. The Non-inferiority of Human Papillomavirus Vaccine Immunogenicity Among Women Over 26 Years: A Systematic Review;Cureus;2024-07-22

4. Tuning of plasma cell lifespan by competition explains the longevity and heterogeneity of antibody persistence;Immunity;2024-03

5. Adjuvant Human Papillomavirus Vaccination in Recurrent Respiratory Papilloma Patients Older than 45;The Laryngoscope;2024-02-24